Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Biokiller is an oral biological antimicrobial gel containing antimicrobial peptides (AMPs) developed for the treatment of periodontitis. It is primarily used as an adjunct to non-surgical periodontal therapy, such as scaling and root planing (SRP), particularly in patients with Stage III and Grade B periodontitis. The gel is applied locally into the periodontal pocket where the antimicrobial peptides target and disrupt bacterial biofilms and cell membranes. This approach aims to provide a targeted antimicrobial effect while avoiding the common side effects of broad-spectrum antibiotics, such as the development of drug resistance, tooth staining, and the depletion of beneficial oral probiotics. The product was evaluated in clinical trials led by the Beijing Stomatological Hospital, Capital Medical University.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Biokiller.